Dual requirement for STAT signaling in dendritic cell immunobiology.

[1]  T. Kuzel,et al.  Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer , 2017, The Journal of Immunology.

[2]  T. Anagnostou,et al.  The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation , 2016, Front. Immunol..

[3]  Jiayuh Lin,et al.  STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells , 2016, International journal of oncology.

[4]  C. Figdor,et al.  Dendritic Cell–Based Immunotherapy: State of the Art and Beyond , 2016, Clinical Cancer Research.

[5]  Letizia Da Sacco,et al.  HIV-1 gp120 influences the expression of microRNAs in human monocyte-derived dendritic cells via STAT3 activation , 2015, BMC Genomics.

[6]  L. Zitvogel,et al.  Type I interferons in anticancer immunity , 2015, Nature Reviews Immunology.

[7]  Xinchen Sun,et al.  STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma , 2015, Tumor Biology.

[8]  B. Jenkins,et al.  STAT1 plays a role in TLR signal transduction and inflammatory responses , 2014, Immunology and cell biology.

[9]  D. Ma,et al.  Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer , 2014, Oncotarget.

[10]  Letizia Da Sacco,et al.  HIV-1 gp120 Activates the STAT3/Interleukin-6 Axis in Primary Human Monocyte-Derived Dendritic Cells , 2014, Journal of Virology.

[11]  S. Gessani,et al.  STAT3-silenced human dendritic cells have an enhanced ability to prime IFNγ production by both αβ and γδ T lymphocytes. , 2014, Immunobiology.

[12]  G. Stark,et al.  Interferons and their stimulated genes in the tumor microenvironment. , 2014, Seminars in oncology.

[13]  Yamei Chen,et al.  STAT inhibitors for cancer therapy , 2013, Journal of Hematology & Oncology.

[14]  Fei Li,et al.  Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer. , 2013, Cancer letters.

[15]  C. Figdor,et al.  The nature of activatory and tolerogenic dendritic cell-derived signal II , 2013, Front. Immunol..

[16]  Yunbao Pan,et al.  Stat3 Inhibitor Stattic Exhibits Potent Antitumor Activity and Induces Chemo- and Radio-Sensitivity in Nasopharyngeal Carcinoma , 2013, PloS one.

[17]  S. Gessani,et al.  Revisiting the specificity of small molecule inhibitors: the example of stattic in dendritic cells. , 2012, Chemistry & biology.

[18]  N. Neamati,et al.  Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. , 2012, Journal of medicinal chemistry.

[19]  V. Sexl,et al.  Conditional Stat1 Ablation Reveals the Importance of Interferon Signaling for Immunity to Listeria monocytogenes Infection , 2012, PLoS pathogens.

[20]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[21]  K. Takeda,et al.  Enhanced Cancer Immunotherapy Using STAT3-Depleted Dendritic Cells with High Th1-Inducing Ability and Resistance to Cancer Cell-Derived Inhibitory Factors , 2011, The Journal of Immunology.

[22]  Ira Mellman,et al.  Designing vaccines based on biology of human dendritic cell subsets. , 2010, Immunity.

[23]  G. Lesinski,et al.  The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity , 2010, Molecular Cancer.

[24]  Courtney R. Plumlee,et al.  Dendritic Cell (DC)-Specific Targeting Reveals Stat3 as a Negative Regulator of DC Function , 2010, The Journal of Immunology.

[25]  T. Rülicke,et al.  Dendritic Cells Require STAT-1 Phosphorylated at Its Transactivating Domain for the Induction of Peptide-Specific CTL1 , 2009, The Journal of Immunology.

[26]  X. Qin,et al.  The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. , 2008, Immunity.

[27]  G. Stark,et al.  Roles of unphosphorylated STATs in signaling , 2008, Cell Research.

[28]  William A Weiss,et al.  Recognizing and exploiting differences between RNAi and small-molecule inhibitors. , 2007, Nature chemical biology.

[29]  R. Steinman,et al.  Dendritic cells: Understanding immunogenicity , 2007, European journal of immunology.

[30]  P. Scott,et al.  STAT1 Expression in Dendritic Cells, but Not T Cells, Is Required for Immunity to Leishmania major1 , 2007, The Journal of Immunology.

[31]  C. Parish,et al.  Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester , 2007, Nature Protocols.

[32]  Bianca Sperl,et al.  Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. , 2006, Chemistry & biology.

[33]  A. Lanzavecchia,et al.  Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon–producing and dendritic cell development , 2006, The Journal of experimental medicine.

[34]  Hua Yu,et al.  Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity , 2005, Nature Medicine.

[35]  Giuseppe Penna,et al.  Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. , 2005, Blood.

[36]  Daniele M. Gilkes,et al.  Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling1 , 2005, The Journal of Immunology.

[37]  S. Ebong,et al.  Dendritic Cell Maturation Requires STAT1 and Is under Feedback Regulation by Suppressors of Cytokine Signaling , 2004, The Journal of Immunology.

[38]  R. Jove,et al.  Hyperactivation of STAT3 Is Involved in Abnormal Differentiation of Dendritic Cells in Cancer , 2004, The Journal of Immunology.

[39]  Hua Yu,et al.  Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells , 2004, Nature Medicine.

[40]  R. Flavell,et al.  STAT3 is required for Flt3L-dependent dendritic cell differentiation. , 2003, Immunity.

[41]  D. Mancini,et al.  High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. , 2003, Transplant immunology.

[42]  F. Belardelli,et al.  Loss of Type I IFN Receptors and Impaired IFN Responsiveness During Terminal Maturation of Monocyte-Derived Human Dendritic Cells1 , 2002, The Journal of Immunology.

[43]  K. Heeg,et al.  Signal integration following Toll-like receptor triggering. , 2002, Critical reviews in immunology.

[44]  J. Fay,et al.  Dendritic Cells , 2003, Annals of the New York Academy of Sciences.